Travere Therapeutics Announces Outcome Of Type A Meeting With FDA In Which Alignment Was Reached Plan To Submit Additional Estimated Glomerular Filtration Rate Data From The Phase 3 Duplex Study Of Sparsentan To Support An Application For 2022